NCT04655677已完成1 期
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events
研究概览
简要总结
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
详细描述
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Baseline testing, Lymphodepleting, C-CAR039 infusion, and Follow-up Visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70 years (include 18 and 70), male or female;
- •Expected survival ≥ 12 weeks
- •ECOG score 0-2
- •CD19 or CD20 positive B-NHL confirmed by cytology or histology according to WHO2016 criteria, including DLBCL, PMBCL, tFL, FL and MCL
- •Relapsed or refractory disease after ≥ 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT);
- •For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause of intolerance should be recorded;
- •No contraindications of apheresis.
- •At least one measurable lesion according to Lugano 2014 criteria;
- •Adequate organ and bone marrow function
- •The patient volunteered to participate in the study and signed the Informed Consent.
排除标准
- •Malignant tumors other than diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma within 5 years before screening, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation and breast ductal carcinoma in situ after radical operation;
- •Active HIV, HBV, HCV or treponema pallidum infection;
- •Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy
- •Any other uncontrolled active disease that hinders participation in the trial;
- •Any situation that the investigator believes would compromise the safety of the subject or interfere with the purpose of the study;
- •Female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after C-CAR039 infusion;
- •Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
- •Patients who have previously been infected with tuberculosis.
- •Administered Corticosteroids and/or other immunosuppressants within 7 days before apheresis. and 5 days before the infusion of C-CAR039;
- •Patients with central nervous system involvement;
- •Any systemic antitumor therapy performed within 2 weeks before enrollment;
- •Those with medical conditions that prevent them from signing the written informed consent or from complying with the study procedures; or those who are unwilling or unable to comply with the study requirements;
- •Other conditions was considered unsuitable for enrollment by the investigator.
研究组 & 干预措施
Prizloncabtagene Autoleucel
Experimental
Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
干预措施: Prizloncabtagene Autoleucel (Biological)
结局指标
主要结局
Incidence and severity of adverse events
时间窗: Up to 24 months after C-CAR039 infusion
Incidence and severity of adverse events after C-CAR039 infusion according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 criteria
次要结局
- Maximum concentration of C-CAR039 in the peripheral blood (Cmax)(Up to 24 Months after C-CAR039 infusion)
- Time to maximum concentration of C-CAR039 in the peripheral blood (Tmax)(Up to 24 Months after C-CAR039 infusion)
- Tlast of C-CAR039 in the peripheral blood after infusio (Tlast)(Up to 24 Months after C-CAR039 infusion)
- AUC0h-28d of C-CAR039 in the peripheral blood (AUC0-28d)(Up to 28 days after C-CAR039 infusion)
- Overall response rate (ORR)(Up to 24 Months after C-CAR039 infusion)
- Duration of response (DOR)(Up to 24 Months after C-CAR039 infusion)
- Progression-free survival (PFS)(Up to 24 Months after C-CAR039 infusion)
- Overall survival (OS)(Up to 24 Months after C-CAR039 infusion)
研究者
Yan Zhang, MD
Chief Physician
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid TumorsNCT05344976Peking University12
已完成
1 期
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaMultiple MyelomaNCT04322292Institute of Hematology & Blood Diseases Hospital, China9
Unknown
1 期
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT03815383The First Affiliated Hospital with Nanjing Medical University12
已完成
不适用
LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaAcute Myelogenous LeukemiaChronic Myelomonocytic LeukemiaNCT05739409Institute of Hematology & Blood Diseases Hospital, China1
尚未招募
不适用
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid TumorsSolid TumorNCT05745454su haichuan12